AR071631A1 - Uso de un compuesto de quinilinil -4-oxi- fenil- ciclopropildicarboxamida y un inhibidor de erbb para preparar un medicamento util para el tratamiento de canceres - Google Patents
Uso de un compuesto de quinilinil -4-oxi- fenil- ciclopropildicarboxamida y un inhibidor de erbb para preparar un medicamento util para el tratamiento de canceresInfo
- Publication number
- AR071631A1 AR071631A1 ARP090101611A ARP090101611A AR071631A1 AR 071631 A1 AR071631 A1 AR 071631A1 AR P090101611 A ARP090101611 A AR P090101611A AR P090101611 A ARP090101611 A AR P090101611A AR 071631 A1 AR071631 A1 AR 071631A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- erbb
- erbb inhibitor
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Uso de: a) un compuesto de quinilinil-4-oxi-fenil-ciclopropildicarboxamida de la formula (1) o una sal farmacéuticamente aceptable del mismo; y (b) un inhibidor de erbB que inhibe el receptor erbB-1 o erbB-2 o erbB-3 o una combinacion de los mismos; en la que R1 es alquilo C1-6; R2 es alquilo C1-6 o -(CH2)n-N(R5)2; R3 es Cl o F; R4 es CI o F; cada R5 es independientemente alquilo C1-6 o, junto con el átomo de nitrogeno al que están unidos, forman un grupo morfolino, piperidinilo o pirazinilo; n es 2, 3 o 4; p es 0 o 1; y q es 0, 1 o 2, para preparar un medicamento util para el tratamiento de cánceres en un paciente. El uso de un compuesto de formula (1) que es el compuesto de formula (2) o una sal farmacéuticamente aceptable del mismo, para tratar a un paciente que padece cáncer de mama o cáncer de cabeza de cuello. Dichos usos del compuesto o sal farmacéuticamente aceptable de formula (1); o el inhibidor de erbB; o una combinacion de los mismos que incluye un excipiente farmacéuticamente aceptable. Estos usos son para una terapia combinada más eficaz que las terapias descritas previamente. Reivindicacion 8: El uso de cualquiera de las reivindicaciones 1 a 3, caracterizado porque el inhibidor de erbB es trastuzumab. Reivindicacion 9: El uso de cualquiera de las reivindicaciones 1 a 3, caracterizado porque el inhibidor de erbB es cetuximab.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5032208P | 2008-05-05 | 2008-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071631A1 true AR071631A1 (es) | 2010-06-30 |
Family
ID=41257222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101611A AR071631A1 (es) | 2008-05-05 | 2009-05-05 | Uso de un compuesto de quinilinil -4-oxi- fenil- ciclopropildicarboxamida y un inhibidor de erbb para preparar un medicamento util para el tratamiento de canceres |
Country Status (19)
Country | Link |
---|---|
US (3) | US20090274693A1 (es) |
EP (1) | EP2274304A4 (es) |
JP (1) | JP2011519941A (es) |
KR (1) | KR20110004462A (es) |
CN (1) | CN102083824A (es) |
AR (1) | AR071631A1 (es) |
AU (1) | AU2009244453B2 (es) |
BR (1) | BRPI0912582A2 (es) |
CA (1) | CA2723699A1 (es) |
CL (1) | CL2009001063A1 (es) |
EA (1) | EA020779B1 (es) |
IL (1) | IL209057A0 (es) |
MX (1) | MX2010012101A (es) |
PE (1) | PE20091832A1 (es) |
SG (1) | SG190623A1 (es) |
TW (1) | TW201006829A (es) |
UY (1) | UY31800A (es) |
WO (1) | WO2009137429A1 (es) |
ZA (1) | ZA201007722B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2629244C (en) | 2005-11-11 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
HUE061117T2 (hu) | 2009-03-25 | 2023-05-28 | Genentech Inc | Anti-FGFR3 antitestek és eljárások alkalmazásukra |
ES2731901T3 (es) | 2009-07-06 | 2019-11-19 | Boehringer Ingelheim Int | Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo |
WO2011014457A1 (en) * | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
WO2011014872A2 (en) * | 2009-07-31 | 2011-02-03 | The Johns Hopkins University | Compositions and methods for diagnosing, treating or preventing neoplasias |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
TWI630916B (zh) * | 2009-11-13 | 2018-08-01 | 第一三共歐洲公司 | 供治療或預防人表皮生長因子受體-3(her-3)相關疾病之藥料和方法 |
ES2904646T3 (es) | 2010-07-16 | 2022-04-05 | Exelixis Inc | Composiciones farmacéuticas moduladoras de c-Met |
PT2606070T (pt) | 2010-08-20 | 2017-03-31 | Novartis Ag | Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
KR20140002711A (ko) * | 2010-12-23 | 2014-01-08 | 네스텍 소시에테아노님 | 항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법 |
CN102532109B (zh) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | 一种拉帕替尼及其盐的合成方法 |
CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
TW201309650A (zh) | 2011-02-10 | 2013-03-01 | Exelixis Inc | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
BR212013028314U2 (pt) * | 2011-05-02 | 2015-11-03 | Exelixis Inc | método para tratar câncer e dor de câncer de osso |
UA115866C2 (uk) | 2011-09-22 | 2018-01-10 | Екселіксіс, Інк. | Спосіб лікування остеопорозу |
HUE048023T2 (hu) | 2011-10-20 | 2020-05-28 | Exelixis Inc | Eljárás kinolin-származékok elõállítására |
SG10201510307WA (en) | 2011-11-14 | 2016-01-28 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
KR102083957B1 (ko) * | 2011-12-05 | 2020-03-04 | 노파르티스 아게 | 표피 성장 인자 수용체 3 (her3)에 대한 항체 |
TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
NZ627586A (en) | 2012-01-31 | 2016-08-26 | Daiichi Sankyo Co Ltd | Pyridone derivatives |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
CN103664879A (zh) * | 2012-09-17 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
WO2014093750A1 (en) * | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
NZ712330A (en) | 2013-03-15 | 2020-04-24 | Exelixis Inc | Metabolites of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
TWI649308B (zh) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
KR102478402B1 (ko) | 2013-10-14 | 2022-12-15 | 얀센 바이오테크 인코포레이티드 | 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자 |
UA120607C2 (uk) * | 2014-02-04 | 2020-01-10 | Астеллас Фарма Інк. | Фармацевтична композиція, яка включає діаміно-гетероциклічну карбоксамідну сполуку як активний інгредієнт |
BR112016018450A2 (pt) | 2014-02-14 | 2018-09-18 | Exelixis Inc | formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso |
EP3119476A1 (en) | 2014-03-17 | 2017-01-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
BR112016020135A8 (pt) * | 2014-04-03 | 2021-07-06 | Merck Patent Gmbh | mistura de composto, seus usos, composição farmacêutica, e conjunto (kit) |
KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
WO2016104617A1 (ja) | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | キノリン誘導体 |
FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
WO2017181187A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
US10662235B2 (en) | 2016-06-21 | 2020-05-26 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
CN107235897B (zh) * | 2016-09-27 | 2019-08-16 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク,インコーポレーテツド | Cd8a結合フィブロネクチンiii型ドメイン |
CA3051605A1 (en) | 2017-01-26 | 2018-08-02 | Ono Pharmaceutical Co., Ltd. | Ethane-sulfonate salt of quinoline derivative |
EP3583943A4 (en) | 2017-02-15 | 2020-12-30 | Taiho Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION |
US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
JP2022551204A (ja) | 2019-10-14 | 2022-12-07 | アロ・バイオセラピューティクス・カンパニー | Cd71結合フィブロネクチンiii型ドメイン |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1353693B1 (en) * | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
CA2537812C (en) * | 2003-09-26 | 2013-01-22 | Exelixis, Inc. | C-met modulators and method of use |
ITRM20030475A1 (it) * | 2003-10-15 | 2005-04-16 | Sipa Societa Industrializzazione P Rogettazione E | Impianto e metodo per il condizionamento termico di oggetti |
UA96139C2 (uk) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
CN101370519B (zh) * | 2005-12-15 | 2013-07-24 | 阿斯利康(瑞典)有限公司 | 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合 |
US20080058312A1 (en) * | 2006-01-11 | 2008-03-06 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
ES2529790T3 (es) * | 2007-04-13 | 2015-02-25 | Dana-Farber Cancer Institute, Inc. | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB |
JP2010530359A (ja) * | 2007-05-17 | 2010-09-09 | ジェネンテック, インコーポレイテッド | ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造 |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
WO2009036099A1 (en) * | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
-
2009
- 2009-04-30 UY UY0001031800A patent/UY31800A/es not_active Application Discontinuation
- 2009-05-04 PE PE2009000602A patent/PE20091832A1/es not_active Application Discontinuation
- 2009-05-04 TW TW098114669A patent/TW201006829A/zh unknown
- 2009-05-04 CL CL2009001063A patent/CL2009001063A1/es unknown
- 2009-05-05 BR BRPI0912582-5A patent/BRPI0912582A2/pt not_active IP Right Cessation
- 2009-05-05 EA EA201071268A patent/EA020779B1/ru not_active IP Right Cessation
- 2009-05-05 JP JP2011508584A patent/JP2011519941A/ja active Pending
- 2009-05-05 CN CN2009801261595A patent/CN102083824A/zh active Pending
- 2009-05-05 AU AU2009244453A patent/AU2009244453B2/en not_active Ceased
- 2009-05-05 CA CA2723699A patent/CA2723699A1/en not_active Abandoned
- 2009-05-05 US US12/435,473 patent/US20090274693A1/en not_active Abandoned
- 2009-05-05 WO PCT/US2009/042768 patent/WO2009137429A1/en active Application Filing
- 2009-05-05 AR ARP090101611A patent/AR071631A1/es unknown
- 2009-05-05 EP EP09743415A patent/EP2274304A4/en not_active Withdrawn
- 2009-05-05 KR KR1020107027183A patent/KR20110004462A/ko not_active Application Discontinuation
- 2009-05-05 MX MX2010012101A patent/MX2010012101A/es not_active Application Discontinuation
- 2009-05-05 SG SG2013033709A patent/SG190623A1/en unknown
-
2010
- 2010-10-28 ZA ZA2010/07722A patent/ZA201007722B/en unknown
- 2010-11-01 IL IL209057A patent/IL209057A0/en unknown
-
2013
- 2013-01-29 US US13/753,146 patent/US20130150363A1/en not_active Abandoned
- 2013-01-29 US US13/753,031 patent/US20130142790A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2010012101A (es) | 2010-11-30 |
KR20110004462A (ko) | 2011-01-13 |
CN102083824A (zh) | 2011-06-01 |
UY31800A (es) | 2009-11-10 |
JP2011519941A (ja) | 2011-07-14 |
EA201071268A1 (ru) | 2011-06-30 |
WO2009137429A1 (en) | 2009-11-12 |
BRPI0912582A2 (pt) | 2015-07-28 |
EP2274304A4 (en) | 2012-05-30 |
ZA201007722B (en) | 2011-08-31 |
SG190623A1 (en) | 2013-06-28 |
US20130150363A1 (en) | 2013-06-13 |
CA2723699A1 (en) | 2009-11-12 |
AU2009244453B2 (en) | 2012-07-19 |
TW201006829A (en) | 2010-02-16 |
EP2274304A1 (en) | 2011-01-19 |
EA020779B1 (ru) | 2015-01-30 |
IL209057A0 (en) | 2011-01-31 |
CL2009001063A1 (es) | 2010-09-24 |
PE20091832A1 (es) | 2009-12-25 |
AU2009244453A1 (en) | 2009-11-12 |
US20130142790A1 (en) | 2013-06-06 |
US20090274693A1 (en) | 2009-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071631A1 (es) | Uso de un compuesto de quinilinil -4-oxi- fenil- ciclopropildicarboxamida y un inhibidor de erbb para preparar un medicamento util para el tratamiento de canceres | |
CY1119939T1 (el) | Παραγωγα 2,3-διϋδρο-βενζο[1,4]οξαζιν και σχετικες ενωσεις οπως αναστολεις φωσφοϊνοσιτινης-3 κινασης (ρι3κ) για τη θεραπεια παραδειγματος χαρην της ρευματοειδους αρθριτιδας | |
CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
JP2011519941A5 (es) | ||
CY1119642T1 (el) | Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου | |
AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
AR074876A1 (es) | Derivados de indol-pirimidina para tratar cancer | |
CL2020002562A1 (es) | (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
MX2019005706A (es) | Inhibidores de la tirosina quinasa de bruton. | |
EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
EA201590697A1 (ru) | Производные кетамина | |
RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato | |
MX2016014574A (es) | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. | |
RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
EA201490516A1 (ru) | Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ | |
PE20212329A1 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer | |
RU2014152792A (ru) | Пиранопиридоновые ингибиторы танкиразы | |
EA036542B9 (ru) | Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |